Evidence map›Paper›PMID 39875802›Full record

ArticleScientific reports2025

Generation of IgM

Mari Raudstein, Ma Michelle D Peñaranda, Erik Kjærner-Semb, Søren Grove, H Craig Morton, Rolf Brudvik Edvardsen

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mari RaudsteinInstitute of Marine Research, Bergen, Norway.
Ma Michelle D PeñarandaInstitute of Marine Research, Bergen, Norway.
Erik Kjærner-SembInstitute of Marine Research, Bergen, Norway.
Søren GroveInstitute of Marine Research, Bergen, Norway.
H Craig MortonInstitute of Marine Research, Bergen, Norway.
Rolf Brudvik EdvardsenInstitute of Marine Research, Bergen, Norway. rolfbe@hi.no.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infectious diseases pose significant challenges to Norwegian Atlantic salmon aquaculture. Vaccines are critical for disease prevention; however, a deeper understanding of the immune system is essential to improve vaccine efficacy. Immunoglobulin M (IgM) is the main antibody involved in the systemic immune response of teleosts, including Atlantic salmon. In this study, we used CRISPR/Cas9 technology to knock out the two IgM genes in Atlantic salmon. High-throughput sequencing revealed an average mutagenesis efficiency of 97% across both loci, with a predominance of frameshift mutations (78%). Gene expression analyses demonstrated significantly reduced membrane-bound IgM mRNA levels in head kidney and spleen tissues. Flow cytometry revealed a 78% reduction in IgM

Indexed as

B-LymphocytesCRISPR-Cas SystemsGene Knockout TechniquesImmunoglobulin MSalmo salarAnimalsImmunoglobulin MAdaptive immunityAquacultureGene editingIgTImmunoglobulinVaccines

Identifiers

PMID39875802
PMCPMC11775215

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.